Market Overview

UPDATE: Wunderlich Securities Raises PT to $18 on Conceptus; Hologic Settlement

Related CPTS
Bayer Successfully Completes Tender Offer for Conceptus
Benzinga's Top Downgrades

Wunderlich Securities raises its price target from $14 to $18 on Hold-rated Conceptus (NASDAQ: CPTS) following the company's settlement of a suit with Hologic (NASDAQ: HOLX).

Wunderlich Securities comments, "On Monday, Conceptus (CPTS) and Hologic (HOLX-NR) announced that their on-going patent infringement litigation has been settled. Under the terms of the settlement, Hologic's Adiana Permanent Contraception System will be removed from the market by May 18, 2012. Meanwhile, CPTS has agreed to drop its previously jury-awarded $18.8 million which was decided last October. This settlement ends all continuing litigation which includes all the prior appeals. In addition to the settlement, Hologic announced today its acquisition of Gen-Probe Incorporated (GPRO-NR) for $3.75 billion in cash. While not directly related, we believe this may have contributed to HOLX's decision to exit the permanent contraception market."

CPTS closed at $18.77 on Monday.

Latest Ratings for CPTS

DateFirmActionFromTo
Jun 2013WunderlichTerminatesHold
May 2013Raymond JamesDowngradesOutperformMarket Perform
May 2013Roth CapitalDowngradesBuyNeutral

View More Analyst Ratings for CPTS
View the Latest Analyst Ratings

Posted-In: Wunderlich SecuritiesAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (CPTS + HOLX)

Around the Web, We're Loving...

Get Benzinga's Newsletters